['metastatic melanoma']
['vemurafenib', 'lymphodepleting chemotherapy', 'til infusion', 'interleukin-2']

        Inclusion Criteria:

          -  Histologically confirmed unresectable stage III or stage IV metastatic melanoma.

          -  Metastasis available for surgical resection (about 2 cm3) and residual measureable
             disease after resection.

          -  Pathologically verified BRAF mutation.

          -  ECOG performance status 0-1.

          -  Life expectancy ≥ 3 months.

          -  No significant toxicity (CTC ≤ 1) from prior treatments.

          -  Adequate renal, hepatic and hematologic function.

          -  Women of childbearing potential (WOCBP) and men in a sexual relationship with a WOCBP
             must be using an effective method of contraception during treatment and for at least 6
             months after completion of treatment.

          -  Able to comprehend the information given and willing to sign informed consent.

        Exclusion Criteria:

          -  Other malignancies, unless followed for ≥ 5 years with no sign of disease, except
             squamous cell carcinoma or adequately treated carcinoma in situ colli uteri.

          -  Cerebral metastasis. Patients with previously treated CNS metastasis can participate
             if surgically removed or treated with stereotactic radiotherapy if stable > 28 days
             after treatment measured by MRI. Patients with asymptomatic and untreated CNS
             metastasis can participate based on investigators evaluation.

          -  Patients with ocular melanoma.

          -  Previous treatment with a BRAF inhibitor.

          -  Severe allergies, history of anaphylaxis or known allergies to drugs administered.

          -  Serious medical or psychiatric comorbidity.

          -  QTc ≥ 450 ms.

          -  Clearance < 70 ml/min.

          -  Acute or chronic infection with e.g. HIV, hepatitis, tuberculosis

          -  Active autoimmune disease.

          -  Pregnant og nursing women.

          -  Need for immunosuppressive treatment, e.g. corticosteroids or methotrexate.

          -  Concomitant treatment with other experimental drugs.

          -  Patients with uncontrolled hypercalcemia

          -  More than four weeks must have elapsed since any prior systemic therapy at the time of
             treatment
      